Patients’ individual genomes may affect efficacy, safety of gene editing
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people’s cells, and multiple trials are recruiting or in the planning stages. A new study led by Boston Children’s Hospital and the University of Montreal raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous “off target” effect.
The study adds to evidence that gene editing may need to be adapted to each patient’s genome, to ensure there aren’t variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear this week in the Proceedings of the National Academy of Sciences Early Edition (December 11-15).
“Humans vary in their DNA sequences, and what is taken as the ‘normal’ DNA sequence for reference cannot account for all these differences,” says Stuart Orkin, MD, of Dana-Farber Boston Children’s Cancer and Blood Disorders Center and co-corresponding author on the study with Matthew Canver, an MD-PhD student at Harvard Medical School. “We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns.”
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team, led by Orkin, Canver and Samuel Lessard of the University of Montreal, then looked to see whether any of the 7,444 individuals carried DNA sequence variants (“letter changes” or insertions/deletions) in the areas the gRNAs are looking for.
“If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure,” explains Canver, who conceived and led the study in Orkin’s Boston Children’s Hospital lab. “A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy.”
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place — resulting in an edit of a gene or other DNA region that’s not meant to be targeted.
“In rare cases, there was the potential to create very potent ‘off-target’ sites – where CRISPR reagents could bind and cut where they’re not intended to,” says Canver. “If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern.”
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
“The unifying theme is that all these technologies rely on identifying stretches of DNA bases very specifically,” says Canver. “So, a variant that affects the target sequence could reduce guide RNA binding. Variants can also lead to binding at new sites that could potentially cause harm. As these gene-editing therapies continue to develop and start to approach the clinic, it’s important to make sure each therapy is going to be tailored to the patient that’s going to be treated.”
The Latest on: Gene editing
Gene Editing Medicine Breakthroughs
on April 18, 2018 at 2:31 pm
New techniques improve precision of gene editing technology, replacing the natural guide molecule currently used with a synthetic one called BNA which promises to bring the applications closer to therapeutic reality. Imagine, if you will, a future in which ... […]
Gates backs gene technologies in fight to end malaria
on April 18, 2018 at 11:22 am
LONDON, April 18 (Reuters) - Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said on Wednesday, and ethical concerns should not block progress in such gene-modifying research. Speaking at ... […]
Leptin's neural circuit identified—Genome-editing study reveals how hormone helps prevent both obesity and diabetes
on April 18, 2018 at 10:01 am
Subsequently, however, most scientists had discarded that idea because deleting leptin receptors in AgRP neurons using the popular Cre-LoxP gene editing system had failed to replicate either obesity or diabetes found in mice bred to lack leptin receptors. […]
Breakthrough CRISPR Gene Editing Trial Set to Begin This Year
on April 16, 2018 at 3:08 am
Biotech company CRISPR Therapeutics is set to treat Europe’s patients with the CRISPR gene-editing tool this year following regulatory approval for trials. Researchers will apply the much-hyped tool to patients with beta thalassaemia, an inherited ... […]
Is This Tomato Engineered? Inside the Coming Battle Over Gene-Edited Food
on April 15, 2018 at 2:56 pm
Zachary Lippman, a plant biologist at Cold Spring Harbor Laboratory, stood among 2 acres of his experimental crops, including some altered with a gene-editing technology called Crispr-Cas9, one of the most ambitious efforts yet to improve on what nature ... […]
Is Gene Editing the Future of Farming?
on April 15, 2018 at 10:50 am
A research team at Cold Spring Harbor Laboratory is developing higher-yielding tomato plants with a gene-editing tool called Crispr-Cas9. Are these products different from traditional GMOs? Photo: Richard Beaven for The Wall Street Journa […]
Breakthrough brings gene-editing medicine one step closer to patient applications
on April 13, 2018 at 2:42 pm
A UAlberta study led by Basil Hubbard is bringing gene-editing technology closer to therapeutic reality by making it more precise. Credit: Ross Neitz Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each ... […]
Gene-editing patient applications closer with new technique
on April 13, 2018 at 11:20 am
April 13 (UPI) --A new technique in gene editing greatly improves the technology's precision, so much so that it may one day treat some genetic diseases, according to a new study. At the University of Alberta, researchers have improved the accuracy using ... […]
Bill Gates says it would be a 'tragedy' to pass up a controversial, revolutionary gene-editing technology
on April 12, 2018 at 6:58 am
Bill Gates is advocating for the use of genetic editing tools like CRISPR. CRISPR allows scientists to edit DNA, eliminating undesirable genes and potentially swapping in preferable alternatives. Gates thinks we could use genetic editing to make livestock ... […]
via Google News and Bing News